Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
Company profile
Ticker
IMMU
Exchange
Website
CEO
Harout Semerjian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
611009366
IMMU stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Nov 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
EFFECT
Notice of effectiveness
30 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Oct 20
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Oct 20
Latest ownership filings
SC 13G/A
Point72 Asset Management, L.P.
16 Feb 21
SC 13G/A
BlackRock Inc.
9 Nov 20
4
William Fricker
27 Oct 20
4
Behzad Aghazadeh
23 Oct 20
4
Usama Malik
23 Oct 20
4
Scott A Canute
23 Oct 20
4
Robert Azelby
23 Oct 20
4
PETER BARTON HUTT
23 Oct 20
4
LORETTTA M ITRI
23 Oct 20
4
Kurt J. Andrews
23 Oct 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Jun 18 | Jun 17 | Jun 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 974.61 mm | 974.61 mm | 974.61 mm | 974.61 mm | 974.61 mm | 974.61 mm |
Cash burn (monthly) | (no burn) | (no burn) | 22.17 mm | 27.49 mm | 10.27 mm | 14.82 mm |
Cash used (since last report) | n/a | n/a | 1.01 bn | 1.26 bn | 469.25 mm | 676.74 mm |
Cash remaining | n/a | n/a | -37.82 mm | -280.90 mm | 505.35 mm | 297.87 mm |
Runway (months of cash) | n/a | n/a | -1.7 | -10.2 | 49.2 | 20.1 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|